{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T17:28:24Z","timestamp":1693243704460},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,3,24]],"date-time":"2011-03-24T00:00:00Z","timestamp":1300924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s10549-011-1448-8","type":"journal-article","created":{"date-parts":[[2011,3,23]],"date-time":"2011-03-23T05:53:39Z","timestamp":1300859619000},"page":"211-219","source":"Crossref","is-referenced-by-count":6,"title":["Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter?"],"prefix":"10.1007","volume":"129","author":[{"given":"Jan T.","family":"Lowery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Byers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kittelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Hokanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Mouchawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Merrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Hines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenakshi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,24]]},"reference":[{"issue":"23","key":"1448_CR1","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/jnci\/91.23.2020","volume":"91","author":"PL Porter","year":"1999","unstructured":"Porter PL, El-Bastawissi AY, Mandelson MT et al (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91(23):2020\u20132028","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"1448_CR2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/jnci\/92.9.743","volume":"92","author":"FD Gilliland","year":"2000","unstructured":"Gilliland FD, Joste N, Stauber PM et al (2000) Biologic characteristics of interval and screen-detected cancers. J Natl Cancer Inst 92(9):743\u2013749","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1448_CR3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0002-9440(10)61687-2","volume":"159","author":"M Crosier","year":"2001","unstructured":"Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR (2001) High expression of the trefoil protein TFF1 in interval breast cancers. Am J Pathol 159(1):215\u2013221","journal-title":"Am J Pathol"},{"issue":"2","key":"1448_CR4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1054\/brst.2000.0217","volume":"10","author":"MA Raja","year":"2001","unstructured":"Raja MA, Hubbard A, Salman AR (2001) Interval breast cancer: is it a different type of breast cancer? Breast 10(2):100\u2013108","journal-title":"Breast"},{"issue":"2","key":"1448_CR5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1054\/brst.2001.0371","volume":"11","author":"CE Crane","year":"2002","unstructured":"Crane CE, Luke CG, Rogers JM, Playford PE, Roder DM (2002) An analysis of factors associated with interval as opposed to screen-detected breast cancers, including hormone therapy and mammographic density. Breast 11(2):131\u2013136","journal-title":"Breast"},{"issue":"3","key":"1448_CR6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1148\/radiology.199.3.8638010","volume":"199","author":"HC Burrell","year":"1996","unstructured":"Burrell HC, Sibbering DM, Wilson A et al (1996) Screening interval cancers: mammographic features and prognosis factors. Radiology 199(3):811\u2013817","journal-title":"Radiology"},{"issue":"5","key":"1448_CR7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/bjc.1997.135","volume":"75","author":"PJ Klemi","year":"1997","unstructured":"Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H (1997) Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 75(5):762\u2013766","journal-title":"Br J Cancer"},{"key":"1448_CR8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/jcp.53.2.140","volume":"53","author":"WK Cowan","year":"2000","unstructured":"Cowan WK, Angus B, Cray JC, Lunt LG, Ramedan Al-Tamimi S (2000) A study of interval breast cancer within the NHS breast screening programme. J Clin Path 53:140\u2013146","journal-title":"J Clin Path"},{"key":"1448_CR9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ijc.1511","volume":"94","author":"H Wang","year":"2001","unstructured":"Wang H, Bjurstam N, Bjorndal H et al (2001) Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HRT. Int Jr Cancer 94:594\u2013598","journal-title":"Int Jr Cancer"},{"key":"1448_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/ejso.2002.1390","volume":"29","author":"RPR Groenendijk","year":"2003","unstructured":"Groenendijk RPR, Bult P, Noppen AM, Boetes C, Ruers TJM, Wobbes T (2003) Mitotic activity in interval breast cancers. Eur J Surg Oncol 29:29\u201331","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"1448_CR11","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/1055-9965.EPI-04-0394","volume":"14","author":"K Collett","year":"2005","unstructured":"Collett K, Stefansson IM, Eide J et al (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen-detected tumors. Cancer Epidemiol Biomarkers Prev 14(5):1108\u20131112","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"1448_CR12","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1220::AID-CNCR8>3.0.CO;2-D","volume":"78","author":"CT Brekelmans","year":"1996","unstructured":"Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ (1996) Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 78(6):1220\u20131228","journal-title":"Cancer"},{"issue":"10","key":"1448_CR13","first-page":"2682","volume":"5","author":"M Crosier","year":"1999","unstructured":"Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR (1999) Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 5(10):2682\u20132688","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1448_CR14","first-page":"4213","volume":"23","author":"J Anttinen","year":"2003","unstructured":"Anttinen J, Kuopio T, Nykanen M, Tirjjeki H, Saari U, Juhola M (2003) Her-2\/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers. Anticancer Res 23(5):4213\u20134218","journal-title":"Anticancer Res"},{"issue":"5","key":"1448_CR15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/1055-9965.EPI-04-0394","volume":"14","author":"K Collett","year":"2005","unstructured":"Collett K, Stefansson IM, Eide J et al (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen-detected tumors. Cancer Epidemiol Biomarker Prev 14(5):1108\u20131112","journal-title":"Cancer Epidemiol Biomarker Prev"},{"key":"1448_CR16","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ Vijver Van de","year":"2002","unstructured":"Van de Vijver MJ, He YD, Van\u2019t Veer L et al (2002) A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999\u20132009","journal-title":"N Engl J Med"},{"key":"1448_CR17","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24816","volume":"116","author":"MF Rimawi","year":"2010","unstructured":"Rimawi MF, Shetty PB, Weiss HL et al (2010) Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 116:1234\u20131242","journal-title":"Cancer"},{"issue":"21","key":"1448_CR18","first-page":"8993","volume":"68","author":"JT Lowery","year":"2010","unstructured":"Lowery JT, Byers T, Hokanson JE, Kittelson J, Lewin J, Risendal B, Singh M, Mouchawar J (2010) Complementary approaches to assessing risk factors for interval breast cancer. Cancer Causes Control 68(21):8993\u20138997","journal-title":"Cancer Causes Control"},{"key":"1448_CR19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1200\/JCO.1994.12.5.888","volume":"12","author":"AJ Nixon","year":"1994","unstructured":"Nixon AJ, Neeuberg D, Hayes DF (1994) Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12:888\u2013894","journal-title":"J Clin Oncol"},{"issue":"19","key":"1448_CR20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djh269","volume":"96","author":"DS Buist","year":"2004","unstructured":"Buist DS, Porter PL, Lehman C, Taplin SH, White E (2004) Factors contributing to mammography failure in women aged 40\u201349\u00a0years. J Natl Cancer Inst 96(19):1432\u20131440","journal-title":"J Natl Cancer Inst"},{"key":"1448_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1023\/A:1006498721508","volume":"63","author":"M Agrup","year":"2000","unstructured":"Agrup M, Stal O, Olsen K, Wingren S (2000) C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 63:23\u201329","journal-title":"Breast Cancer Res Treat"},{"key":"1448_CR22","first-page":"678","volume":"52","author":"DF Easton","year":"1993","unstructured":"Easton DF, Bishop DT, Ford D, Crodkford GP (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The breast cancer linkage consortium. Am J Hum Genet 52:678\u2013701","journal-title":"Am J Hum Genet"},{"key":"1448_CR23","first-page":"107","volume":"18","author":"KA Phillips","year":"2000","unstructured":"Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18:107\u2013112","journal-title":"J Clin Oncol"},{"issue":"3","key":"1448_CR24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000078165","volume":"6","author":"H Anton-Culver","year":"2003","unstructured":"Anton-Culver H, Ziogas A, Bowen D et al (2003) The cancer genetics network: recruitment results and pilot studies. Community Genet 6(3):171\u2013177","journal-title":"Community Genet"},{"issue":"4","key":"1448_CR25","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0002-9440(10)64075-8","volume":"158","author":"A Hoos","year":"2001","unstructured":"Hoos A, Urist MJ, Stojadinovic A et al (2001) Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the exampl of human fibroblastic tumors. Am J Pathol 158(4):1245\u20131251","journal-title":"Am J Pathol"},{"issue":"11","key":"1448_CR26","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.5858\/2003-127-1451-NSIBCM","volume":"127","author":"KC Lear-Kaul","year":"2003","unstructured":"Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK, McGavran L, Singh M (2003) Her2-neu status in breast cancer metastasis to the central nervous system. Arch Pathol Lab Med 127(11):1451\u20131457","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"1448_CR27","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, Her2 status, prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736\u2013750","journal-title":"J Natl Cancer Inst"},{"key":"1448_CR28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM198309223091206","volume":"309","author":"JD Emerson","year":"1983","unstructured":"Emerson JD, Colditz GA (1983) Use of stastical analysis. N Eng J Med 309:709\u2013713","journal-title":"N Eng J Med"},{"key":"1448_CR29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/modpathol.2009.188","volume":"23","author":"B Vegt Van der","year":"2010","unstructured":"Van der Vegt B, Wesseling J, Pijnappel R (2010) Aggressiveness of \u2018true\u2019 interval invasive ductal carcinomas of the breast in postmenopausal women. Modern Pathology 23:629\u2013636","journal-title":"Modern Pathology"},{"key":"1448_CR30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/1097-0142(19910815)68:4<867::AID-CNCR2820680432>3.0.CO;2-H","volume":"68","author":"WR Bezwoda","year":"1991","unstructured":"Bezwoda WR, Esser JD, Danwey R, Kessel I, Rad MM, Lange M (1991) The value of estrogen and progesterone receptor determinations in advanced breast cancer. Cancer 68:867\u2013872","journal-title":"Cancer"},{"key":"1448_CR31","unstructured":"Dickson RB, Lippman ME (1995) Molecular basis of breast cancer. In: Mendelsohn J, Howley PH, Israel MA (eds) The molecular basis of cancer, 2nd edn. WB Sanders Co., Philadelphia, PA"},{"key":"1448_CR32","first-page":"1","volume":"12","author":"S Badve","year":"2010","unstructured":"Badve S, Dabbs DJ, Schnitt SJ et al (2010) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology November 12:1\u201310","journal-title":"Modern Pathology November"},{"issue":"1","key":"1448_CR33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PPO.0b013e3181d24fc1","volume":"16","author":"ML Burness","year":"2010","unstructured":"Burness ML, Grushko TA, Olopade OI (2010) Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J 16(1):23\u201332","journal-title":"Cancer J"},{"issue":"1","key":"1448_CR34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","volume":"52","author":"JS Reis-Filho","year":"2008","unstructured":"Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52(1):108\u2013118","journal-title":"Histopathology"},{"key":"1448_CR35","doi-asserted-by":"crossref","unstructured":"Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. J Clin Oncol 24(36):5652\u20135657","DOI":"10.1200\/JCO.2006.06.5664"},{"issue":"9","key":"1448_CR36","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California tumor registry. Cancer 109(9):1721\u20131728","journal-title":"Cancer"},{"issue":"6","key":"1448_CR37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1524-4741.2009.00822.x","volume":"15","author":"CA Parise","year":"2009","unstructured":"Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor (HER2) among women with invasive breast cancer in California, 1999\u20132004. Breast J 15(6):593\u2013602","journal-title":"Breast J"},{"key":"1448_CR38","doi-asserted-by":"crossref","unstructured":"Domingo L, Sala M, Servitja S et al (2010) Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes Control","DOI":"10.1007\/s10552-010-9541-6"},{"issue":"2","key":"1448_CR39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/jms.8.2.77","volume":"8","author":"J McCann","year":"2001","unstructured":"McCann J, Britton PD, Warren RML, Hunnam G (2001) Radiological peer review of interval cancers in the East Anglian breast screening programme: what are we missing? Jr Med Screen 8(2):77\u201382","journal-title":"Jr Med Screen"},{"key":"1448_CR40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/jnci\/84.10.781","volume":"84","author":"L Ma","year":"1992","unstructured":"Ma L, Fishell E, Wright B, Hanna W, Allan S, Boyd NF (1992) Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst 84:781\u2013785","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"1448_CR41","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CH et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21):2492\u20132502","journal-title":"JAMA"},{"issue":"4","key":"1448_CR42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/hupa.2003.60","volume":"34","author":"D Zhang","year":"2003","unstructured":"Zhang D, Salto-Tellez M, Do E, Putti TC, Kiay ES (2003) Evaluation of Her2\/neu onogene status in breast tumors on tissue microarrays. Hum Pathol 34(4):362\u2013368","journal-title":"Hum Pathol"},{"issue":"4785","key":"1448_CR43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levom WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235(4785):177\u2013182","journal-title":"Science"},{"key":"1448_CR44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/crad.2001.0882","volume":"57","author":"K Gower-Thomas","year":"2002","unstructured":"Gower-Thomas K, Fielder H, Branston L, Greening S, Beer H, Rogers C (2002) Reviewing interval cancers: time well spent? Clin Radiol 57:384\u2013388","journal-title":"Clin Radiol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1448-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1448-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1448-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T15:50:52Z","timestamp":1637423452000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1448-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,24]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1448-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,24]]}}}